{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000049","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.424239+00:00","generated_at":"2026-06-02T02:37:30.777922+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024","bullets":["Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.","Cash and equivalents $4.1M as of March 31, 2024; public offering raised $5.5M gross in Feb 2024.","GRI-0621 Phase 2a biomarker study in IPF: interim data Q3 2024, topline results Q4 2024.","GRI-0803 for SLE: IND-enabling studies to complete Q3 2024; IND filing expected H2 2024.","Expanded IP estate with Korean patent issuance and Canadian notice of allowance for NKT cell modulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000049","json":"https://secwatch.observer/filing/0001824293-24-000049.json","markdown":"https://secwatch.observer/filing/0001824293-24-000049.md","text":"https://secwatch.observer/filing/0001824293-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/0001824293-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/val-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:37:30.777922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b4592928976064880bc8816a6fef9eaaf95265c","claim":"GRI Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $1.9 million.","evidence_excerpt":"GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/0001824293-24-000049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $1.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}